TipRanks
Abbott Laboratories (CH:ABT)
:ABT

Abbott Laboratories (ABT) Price & Analysis

2 Followers

ABT Stock Chart & Stats

CHF90.50
-CHF2.00(-2.68%)
At close: 4:00 PM EDT
CHF90.50
-CHF2.00(-2.68%)

Bulls Say, Bears Say

Bulls Say
Diversified, Recurring Healthcare DemandAbbott’s presence across four healthcare segments reduces reliance on any single product category and supports durable demand. Diagnostics reagents, diabetes sensors, nutrition products, and branded medicines also create recurring or repeat purchasing, strengthening revenue resilience over the next several quarters.
Strong And Growing Cash GenerationHigh operating and free cash flow gives Abbott internal funding for research, product launches, acquisitions, debt service, and shareholder returns. The reported growth in free cash flow and close tracking with earnings indicate that current profitability is converting effectively into usable cash.
Broad Product And Innovation MomentumGrowth across cardiovascular devices and continuous glucose monitoring is reinforced by a pipeline spanning structural heart, electrophysiology, IVL, pacing, and wearable monitoring. These launches and milestones can expand Abbott’s addressable markets and support product-led growth beyond the current period.
Bears Say
Meaningfully Higher DebtThe sharp increase in debt leaves Abbott more exposed to refinancing costs and operating setbacks than its prior balance-sheet position. Although equity remains sizable and leverage is moderate, higher obligations can constrain capital allocation if cash generation weakens or conditions become less favorable.
Recent Margin And Returns PressureRecent margin compression and lower return on equity suggest that revenue growth is not translating into profitability as efficiently as before. If this normalization persists, it could reduce earnings conversion, limit operating leverage, and weaken the returns generated from Abbott’s expanding capital base.
Diagnostics And Legal OverhangWeak rapid and molecular diagnostics, combined with continuing China procurement pressure, creates a drag within an otherwise diversified portfolio. The remaining formula litigation also preserves financial and management uncertainty, potentially absorbing cash and attention beyond the announced settlement.

Abbott Laboratories News

ABT FAQ

What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was CHF63.50 and its highest was CHF110.00 in the past 12 months.
    What is Abbott Laboratories’s market cap?
    Abbott Laboratories’s market cap is CHF145.35B.
      When is Abbott Laboratories’s upcoming earnings report date?
      Abbott Laboratories’s upcoming earnings report date is Oct 21, 2026 which is in 23 days.
        How were Abbott Laboratories’s earnings last quarter?
        Abbott Laboratories released its earnings results on Jul 16, 2026. The company reported CHF1.05 earnings per share for the quarter, beating the consensus estimate of CHF1.024 by CHF0.026.
          Is Abbott Laboratories overvalued?
          According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Abbott Laboratories pay dividends?
            Abbott Laboratories pays a Quarterly dividend of CHF0.52 which represents an annual dividend yield of 2.18%. See more information on Abbott Laboratories dividends here
              What is Abbott Laboratories’s EPS estimate?
              Abbott Laboratories’s EPS estimate is 1.14.
                How many shares outstanding does Abbott Laboratories have?
                Abbott Laboratories has 1,730,383,300 shares outstanding.
                  What happened to Abbott Laboratories’s price movement after its last earnings report?
                  Abbott Laboratories reported an EPS of CHF1.05 in its last earnings report, beating expectations of CHF1.024. Following the earnings report the stock price went up 9.589%.
                    Which hedge fund is a major shareholder of Abbott Laboratories?
                    Currently, no hedge funds are holding shares in CH:ABT
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Abbott Laboratories

                      Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

                      Abbott Laboratories (ABT) Earnings & Revenues

                      ABT Company Deck

                      ABT Earnings Call

                      Q2 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      Overall, the call conveyed constructive momentum across Abbott’s diversified portfolio with multiple product and regulatory milestones, gross margin expansion, and raised EPS guidance. Key growth engines — diagnostics (notably cancer testing), nutrition recovery, devices (EP, rhythm management, heart failure) and diabetes/CGM — provide visibility to second-half acceleration. Offsetting risks include a soft respiratory season hurting rapid/molecular diagnostics, China VBP headwinds, structural heart US commercial execution needs, and uncertainty/timing around reimbursement and regulatory approvals for some high-impact products (e.g., CGM reimbursement expansion, Libre Duo FDA clearance). On balance, highlights notably outweigh the lowlights, with achievable near-term drivers and a clear pipeline cadence underpinning positive momentum.View all CH:ABT earnings summaries

                      ABT Net sales Breakdown

                      12.49%12.49%19.06%20.16%48.25%0.04%
                      12.49% Established Pharmaceutical Products
                      19.06% Nutritional Products
                      20.16% Diagnostic Products
                      48.25% Medical Devices
                      0.04% Other
                      tipranks

                      ABT Stock 12 Month Forecast

                      Average Price Target

                      CHF103.11
                      ▲(13.93% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"66":"CHF66","89":"CHF89","112":"CHF112","77.5":"CHF77.5","100.5":"CHF100.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":111.9520872,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF111.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.10649018666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF103.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.87876864,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF92.88</span>\n  </div></div>","useHTML":true}}],"tickPositions":[66,77.5,89,100.5,112],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.5,91.22708363076923,92.95416726153846,94.68125089230769,96.40833452307692,98.13541815384615,99.86250178461538,101.58958541538462,103.31666904615385,105.04375267692308,106.7708363076923,108.49791993846154,110.22500356923076,{"y":111.9520872,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.5,90.54665309128205,91.5933061825641,92.63995927384616,93.68661236512821,94.73326545641027,95.77991854769232,96.82657163897436,97.87322473025641,98.91987782153846,99.96653091282052,101.01318400410257,102.05983709538462,{"y":103.10649018666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.5,89.75990528,90.01981056,90.27971584,90.53962112,90.7995264,91.05943168,91.31933696,91.57924224,91.83914752,92.09905280000001,92.35895808000001,92.61886336,{"y":92.87876864,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":99.752,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.752,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.233,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.268,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.268,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.913,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.888,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.469,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.03,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.057,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.011,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.5,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Boston Scientific
                      ―
                      ―
                      Dexcom
                      ―
                      ―
                      Edwards Lifesciences
                      ―
                      ―
                      Medtronic
                      ―
                      ―
                      GE Healthcare Technologies Inc
                      ―
                      ―
                      Popular Stocks